Study shows ‘hypoglycaemic events can accelerate cognitive decline’ in Alzheimer’ patients

While hypos are a familiar risk for diabetics, what is unfamiliar in the world of Alzheimer’s and dementia research is positive developments in treatment.

Since the earliest forms of dementia were discovered, they have proved a thorn in the side of researchers and scientists as study after study provided one brick wall after another in the hunt for an effective treatment.

Now, however, a new treatment has been described as a potential breakthrough.

Known as lecanemab, the treatment has been found to slow cognitive decline by 27 percent in patients who received the drug once every two weeks for 18 months.

READ MORE: Ray Milland’s health ‘began to deteriorate’ quickly